Cochrane · systematic review · CD011014
Polyunsaturated fatty acid supplementation for drug‐resistant epilepsy
Sarmento Vasconcelos, V, Macedo, CR, de Souza Pedrosa, A, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 1 · 16.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
PUFA compared to Placebo for drug‐resistant epilepsy
Population: patients with drug‐resistant epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure freedom PUFA vs Placebo | RR 20 [2.84, 140.99] | 1 study · 70 participants | Low Downgraded: risk of bias, imprecision |
50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐ Older (19 years or more) PUFA vs Placebo | RR 0.57 [0.19, 1.75] | 2 studies · 78 participants | Low Downgraded: risk of bias, imprecision |
50% reduction in seizures frequency (12 weeks) ‐ Per protocol data ‐ Younger (< 19 years) PUFA vs Placebo | RR 33 [4.77, 228.15] | 1 study · 70 participants | Low Downgraded: risk of bias, imprecision |
50% reduction in seizures frequency (6 weeks) PUFA vs Placebo | RR 4.67 [0.58, 37.52] | 1 study · 58 participants | Moderate Downgraded: imprecision |
Potential adverse effects ‐ not reported PUFA vs Placebo | no estimate extracted | NR | No studies |
Gastrointestinal effects PUFA vs Placebo | RR 0.78 [0.32, 1.89] | 2 studies · 85 participants | Low Downgraded: risk of bias, imprecision |